These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 20232446

  • 1. MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma.
    Parodi S, Perfumo C, Garaventa A, Inga A, Mazzocco K, Defferrari R, Tonini GP, Fronza G, Haupt R.
    Pediatr Blood Cancer; 2010 Aug; 55(2):267-72. PubMed ID: 20232446
    [Abstract] [Full Text] [Related]

  • 2. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.
    Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Scarrà GB, Ghiorzo P, Haupt R, Tonini GP, Fronza G.
    Pediatr Blood Cancer; 2009 Oct; 53(4):576-83. PubMed ID: 19526525
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
    Rihani A, Van Maerken T, De Wilde B, Zeka F, Laureys G, Norga K, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J.
    Pediatr Blood Cancer; 2014 Oct; 61(10):1867-70. PubMed ID: 24391119
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I.
    J Clin Oncol; 2008 May 10; 26(14):2252-7. PubMed ID: 18467716
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma.
    Berthold F, Hunneman DH, Harms D, Käser H, Zieschang J.
    Eur J Cancer; 1992 May 10; 28A(12):1950-4. PubMed ID: 1419287
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
    Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H.
    J Clin Oncol; 2006 Sep 20; 24(27):4434-40. PubMed ID: 16983111
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.